Literature DB >> 12741081

Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report.

Klaus Bodner1, Barbara Bodner-Adler, Klaus Czerwenka, Gernot Hudelist, Oliver Kimberger, Sepp Leodolter, Klaus Mayerhofer.   

Abstract

BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth-muscle neoplasm with fewer than 30 documented cases worldwide. Immunohistochemically, ovarian leiomyosarcomas are characterized by the expression of alpha-smooth muscle actin (alpha-SMA). Until recently, no report investigated the role of bcl-2 expression in primary ovarian leiomyosarcoma. We report the management and an immunohistochemical analysis of bcl-2 in a patient with primary leiomyosarcoma of the ovary. CASE REPORT: The patient, a 71-year-old woman, presented with a history of lower abdominal pain and a palpable mass in the lower abdomen. Surgical exploration revealed a large left adnexal mass that had developed from the left ovary and infiltrated one part of the omentum adherent to the left adnexa. Microscopically the left adnexal tumor consisted of spindle cells arranged in smooth-muscle bundles and fascicles. The tumor was characterized by high cellularity and nuclear polymorphism, as well as patchy necrosis and large areas of hemorrhage. Mitotic activity exceeded 5 mitoses per 10 high-power fields with many atypical mitoses. The tumor appeared encapsulated, and the capsule was partially disrupted by tumor cells. Immunohistochemically, the tumor showed a strong staining reaction for muscle actin, alpha-SMA and neuron-specific enolase, and also a weak reaction for vimentin. Strong staining of bcl-2 was detected, with more than 80% of sarcoma cells positive. According to the FIGO staging system for ovarian cancer, the tumor was classified as a primary ovarian leiomyosarcoma stage III C, and the patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide. Two days after the third cycle of cisplatin/ifosfamid she developed an apoplexy spontaneously and chemotherapy was therefore discontinued. The patient remained without evidence of disease until she died as a result of intercurrent pneumonia 14 months after initial surgery.
CONCLUSIONS: Beside the routine histological and immunohistochemical characteristics of primary ovarian leiomyosarcoma, strong staining for bcl-2 was detected. In order to understand more about the nature and the behaviour of this highly malignant neoplasm and to be able to improve the treatment, the prognostic value of bcl-2 has to be investigated in additional studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741081     DOI: 10.1007/bf03040309

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  22 in total

1.  Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts.

Authors:  J C Reed; H S Talwar; M Cuddy; G Baffy; J Williamson; U R Rapp; G J Fisher
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

2.  Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.

Authors:  E Brambilla; A Negoescu; S Gazzeri; S Lantuejoul; D Moro; C Brambilla; J L Coll
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

Review 3.  Primary ovarian leiomyosarcoma. An immunohistochemical and ultrastructural study.

Authors:  H D Friedman; M T Mazur
Journal:  Arch Pathol Lab Med       Date:  1991-09       Impact factor: 5.534

Review 4.  Primary leiomyosarcoma of the ovary in a perimenarchal female.

Authors:  B J Monk; R Nieberg; J S Berek
Journal:  Gynecol Oncol       Date:  1993-03       Impact factor: 5.482

5.  bcl-2 protein in non-small-cell lung carcinoma.

Authors:  F Pezzella; H Turley; I Kuzu; M F Tungekar; M S Dunnill; C B Pierce; A Harris; K C Gatter; D Y Mason
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

Review 6.  Primary leiomyosarcoma of the ovary: a histological and immunocytochemical study.

Authors:  A Balaton; P Vaury; M C Imbert; M A Mussy
Journal:  Gynecol Oncol       Date:  1987-09       Impact factor: 5.482

7.  Leiomyosarcoma of the ovary.

Authors:  S Dixit; S Singhal; H A Baboo; R K Vyas; J P Neema; R Murthy; U Sooryanaraya
Journal:  J Postgrad Med       Date:  1993 Jul-Sep       Impact factor: 1.476

Review 8.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

9.  Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.

Authors:  Y L Zhai; T Nikaido; T Toki; A Shiozawa; A Orii; S Fujii
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

10.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.

Authors:  G Fontanini; S Vignati; D Bigini; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Bevilacqua
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  4 in total

1.  Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.

Authors:  Klaus Bodner; Barbara Bodner-Adler; Oliver Kimberger; Klaus Czerwenka; Klaus Mayerhofer
Journal:  Wien Klin Wochenschr       Date:  2004-02-28       Impact factor: 1.704

2.  Synchronous leiomyosarcoma and fibroma in a single ovary: A case report and review of the literature.

Authors:  Meng He; Yan-Jie Deng; Dan-Yi Zhao; Yang Zhang; Tao Wu
Journal:  Oncol Lett       Date:  2016-02-17       Impact factor: 2.967

3.  Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.

Authors:  Elena Cojocaru; Githmi Palahepitiva Gamage; John Butler; Desmond P Barton; Khin Thway; Cyril Fisher; Christina Messiou; Aisha B Miah; Shane Zaidi; Spyridon Gennatas; Charlotte Benson; Paul Huang; Robin L Jones
Journal:  Gynecol Oncol Rep       Date:  2021-03-02

4.  Primary perimenarcheal ovarian leiomyosarcoma: A case report and review of the literature.

Authors:  Vilaly Khadjetou; Telmoudi Ely Cheikh; Med Vadel Ahmed Haiba; Med Ahmed Ahmed Cheikh; Boukhary Nadi Mouhamed; Ahmed Bonnahy Abdi
Journal:  Int J Surg Case Rep       Date:  2022-04-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.